代谢组学在肝细胞癌诊疗中的研究进展

doi:10.12114/j.issn.1007-9572.2024.0410

摘要/Abstract

摘要： 肝细胞癌（HCC）是较常见的恶性肿瘤之一，具有高发病率、高死亡率的特点，因此早发现、早诊断、早治疗非常重要。灵敏、便捷的血清学生物标志物可在HCC诊疗中起关键性作用，而甲胎蛋白（AFP）等传统生物标志物已远不能满足临床需求。肝脏是机体重要的代谢器官，HCC的发生和发展与代谢密不可分。代谢组学是新近发展起来的一门学科，在HCC的筛查诊断、机制探索、精准治疗、预后判断、疗效评估中具有一定优势。作为系统生物学的重要组成部分，代谢组学技术可在HCC患者的组织、血液和尿液中筛查出差异表达的代谢产物。这些代谢产物不仅能作为生物标志物用于HCC的早期诊断和预后评估，还可阐明HCC发生和进展过程中的代谢机制，用于研发治疗HCC的新药物及新靶点。本文将对代谢组学在HCC诊疗中的研究进展进行综述，以期为HCC生物学诊断标志物及潜在治疗靶点的筛选提供理论依据。

关键词: 肝细胞癌, 代谢组学, 生物标志物, 诊断, 治疗

Abstract:

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. It is characterized by high morbidity and mortality. Therefore, early detection, early diagnosis and early treatment are very important. Sensitive and convenient serological biomarkers play a key role in the diagnosis and treatment of HCC. However, traditional biomarkers such as alpha-fetoprotein fall far short of the clinical needs. Liver is an important organ of metabolism in the body. The occurrence and development of HCC are closely related to metabolism. Metabolomics is a newly developed subject. It has certain advantages in the screening diagnosis, mechanism exploration, precise treatment, prognosis judgment and efficacy evaluation of HCC. As an important part of systems biology, metabolomics technology can screen differentially expressed metabolites in the tissues, blood and urine of HCC patients. On the one hand, these metabolites can be used as biomarkers for early diagnosis and prognosis evaluation of HCC. On the other hand, these metabolites can also clarify the metabolic mechanism in the development and progression of HCC, which can be used to develop new drugs and new targets for the treatment of HCC. This article reviews the research progress of metabolomics in the diagnosis and treatment of HCC, in order to provide a theoretical basis for the screening of HCC biological diagnostic markers and potential therapeutic targets.

Key words: Hepatocellular carcinoma, Metabolomics, Biomarkers, Diagnosis, Treatment

马晓萱,王荣琦. 代谢组学在肝细胞癌诊疗中的研究进展[J]. 中国全科医学, 2025, 28(08): 1017-1022. DOI: 10.12114/j.issn.1007-9572.2024.0410.
MA Xiaoxuan,WANG Rongqi. Research Progress in Metabolomics for HCC Diagnosis and Treatment[J]. Chinese General Practice, 2025, 28(08): 1017-1022. DOI: 10.12114/j.issn.1007-9572.2024.0410.

参考文献 39

[1]	TOH M R，WONG E Y T，WONG S H，et al. Global epidemiology and genetics of hepatocellular carcinoma[J]. Gastroenterology，2023，164（5）：766-782. DOI：10.1053/j.gastro.2023.01.033.
[2]	SUNG H，FERLAY J，SIEGEL R L，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71（3）：209-249. DOI：10.3322/caac.21660.
[3]	SIM Y K，CHONG M C，GANDHI M，et al. Real-world data on the diagnosis，treatment，and management of hepatocellular carcinoma in the Asia-Pacific：the INSIGHT study[J]. Liver Cancer，2023，13（3）：298-313. DOI：10.1159/000534513.
[4]	中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南（2024年版）[J]. 协和医学杂志，2024，15（3）：532-559.
[5]	YEO Y H，LEE Y T，TSENG H R，et al. Alpha-fetoprotein：past，present，and future[J]. Hepatol Commun，2024，8（5）：e0422. DOI：10.1097/HC9.0000000000000422.
[6]	NICHOLSON J K，LINDON J C，HOLMES E. 'Metabonomics'：understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data[J]. Xenobiotica，1999，29（11）：1181-1189. DOI：10.1080/004982599238047.
[7]	李卓，张娜，徐璞，等. 基于核磁共振波谱的代谢组学分析在肿瘤诊疗中的应用进展[J]. 中华检验医学杂志，2022，45（3）：305-309. DOI：10.3760/cma.j.cn114452-20210929-00609.
[8]	许健明，张铭志. 代谢组学在原发性开角型青光眼中的研究进展及前景[J]. 中华实验眼科杂志，2023，41（12）：1221-1226. DOI：10.3760/cma.j.cn115989-20220518-00224.
[9]	宁振，谭广. 肿瘤代谢：肝癌精准诊疗新视角[J]. 中华外科杂志，2020，58（1）：31-36. DOI：10.3760/cma.j.issn.0529-5815.2020.01.008.
[10]	LIU J K，GENG W，SUN H Y，et al. Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma[J]. Gut，2022，71（6）：1203-1213. DOI：10.1136/gutjnl-2021-325189.
[11]	CAPONIGRO V，TORNESELLO A L，MERCIAI F，et al. Integrated plasma metabolomics and lipidomics profiling highlights distinctive signature of hepatocellular carcinoma in HCV patients[J]. J Transl Med，2023，21（1）：918.
[12]	OZAWA H，HIRAYAMA A，SHOJI F，et al. Comprehensive dipeptide analysis revealed cancer-specific profile in the liver of patients with hepatocellular carcinoma and hepatitis[J]. Metabolites，2020，10（11）：442.
[13]	胡雪芳，王彦，贾孟琪，等. 基于1H-NMR技术的肝癌尿液样品代谢组学研究[J]. 现代生物医学进展，2018，18（24）：4647-4651. DOI：10.13241/j.cnki.pmb.2018.24.009.
[14]	解修峰，孙艳，赵晓航. 肝细胞癌尿代谢组学初步研究[J]. 中华肿瘤杂志，2022，44（3）：252-259.
[15]	HERSHBERGER C E，RODARTE A I，SIDDIQI S，et al. Salivary metabolites are promising non-invasive biomarkers of hepatocellular carcinoma and chronic liver disease[J]. Liver Cancer Int，2021，2（2）：33-44. DOI：10.1002/lci2.25.
[16]	LIANG W Z，ZHAO Y，MENG Q X，et al. The role of long non-coding RNA in hepatocellular carcinoma[J]. Aging，2024，16（4）：4052-4073. DOI：10.18632/aging.205523.
[17]	SAADH M J，HUSSAIN Q M，ALAZZAWI T S，et al. MicroRNA as key players in hepatocellular carcinoma：insights into their role in metastasis[J]. Biochem Genet，2024. DOI：10.1007/s10528-024-10897-0.
[18]	SHETTI D，MALLELA V R，YE W J，et al. Emerging role of circulating cell-free RNA as a non-invasive biomarker for hepatocellular carcinoma[J]. Crit Rev Oncol Hematol，2024，200：104391. DOI：10.1016/j.critrevonc.2024.104391.
[19]	FARES S，WEHRLE C J，HONG H N，et al. Emerging and clinically accepted biomarkers for hepatocellular carcinoma[J]. Cancers，2024，16（8）：1453.
[20]	ZHANG X，WU L N，LI X Q，et al. Whether the Golgi protein 73 could be a diagnostic serological marker in hepatocellular carcinoma：a meta analysis[J]. BMC Gastroenterol，2023，23（1）：85. DOI：10.1186/s12876-023-02685-8.
[21]	LI Z J，MOU L S，GAO H B，et al. Diagnostic accuracy of serum dickkopf-1 protein in diagnosis hepatocellular carcinoma：an updated meta-analysis[J]. Medicine，2019，98（32）：e16725. DOI：10.1097/MD.0000000000016725.
[22]	JIANG D L，ZHANG Y S，WANG Y N，et al. Diagnostic accuracy and prognostic significance of glypican-3 in hepatocellular carcinoma：a systematic review and meta-analysis[J]. Front Oncol，2022，12：1012418. DOI：10.3389/fonc.2022.1012418.
[23]	FENG J，LI J J，WU L W，et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma[J]. J Exp Clin Cancer Res，2020，39（1）：126.
[24]	PAUL B，LEWINSKA M，ANDERSEN J B. Lipid alterations in chronic liver disease and liver cancer[J]. JHEP Rep，2022，4（6）：100479. DOI：10.1016/j.jhepr.2022.100479.
[25]	FOGLIA B，BELTRÀ M，SUTTI S，et al. Metabolic reprogramming of HCC：a new microenvironment for immune responses[J]. Int J Mol Sci，2023，24（8）：7463.
[26]	ERICKSEN R E，LIM S L，MCDONNELL E，et al. Loss of BCAA catabolism during carcinogenesis enhances mTORC1 activity and promotes tumor development and progression[J]. Cell Metab，2019，29（5）：1151-1165.e6. DOI：10.1016/j.cmet.2018.12.020.
[27]	SUN J Q，DING J，SHEN Q S，et al. Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma[J]. J Hepatol，2023，78（3）：627-642. DOI：10.1016/j.jhep.2022.11.017.
[28]	SUN R Q，ZHANG Z Y，BAO R X，et al. Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis[J]. J Hepatol，2022，77（2）：453-466. DOI：10.1016/j.jhep.2022.02.030.
[29]	XIA P，ZHANG H，LU H F，et al. METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression[J]. Cancer Commun，2023，43（3）：338-364. DOI：10.1002/cac2.12403.
[30]	PEÑUELAS-HARO I，ESPINOSA-SOTELO R，CROSAS-MOLIST E，et al. The NADPH oxidase NOX4 regulates redox and metabolic homeostasis preventing HCC progression[J]. Hepatology，2023，78（2）：416-433. DOI：10.1002/hep.32702.
[31]	LI B H，LI Y Z，ZHOU H J，et al. Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma[J]. Hepatology，2024，79（2）：289-306. DOI：10.1097/HEP.0000000000000553.
[32]	GUO W，YAO X H，LAN S Y，et al. Metabolomics and integrated network pharmacology analysis reveal SNKAF decoction suppresses cell proliferation and induced cell apoptisis in hepatocellular carcinoma via PI3K/Akt/P53/FoxO signaling axis[J]. Chin Med，2022，17（1）：76. DOI：10.1186/s13020-022-00628-1.
[33]	陆苑，王艳丽，宋忠军，等. 银杏黄酮苷元联合阿霉素协同抗肝癌的细胞代谢组学研究[J]. 中国中药杂志，2022，47（18）：5040-5051. DOI：10.19540/j.cnki.cjcmm.20220506.401.
[34]	TRIPODI F，BADONE B，VESCOVI M，et al. Methionine supplementation affects metabolism and reduces tumor aggressiveness in liver cancer cells[J]. Cells，2020，9（11）：2491. DOI：10.3390/cells9112491.
[35]	XU K D，DING J，ZHOU L F，et al. Smyd2 promotes hepatocellular carcinoma progression by reprogramming glutamine metabolism via c-Myc/GLS1 axis[J]. Cells，2022，12（1）：25. DOI：10.3390/cells12010025.
[36]	LUO X Q，ZHENG E Z，WEI L，et al. The fatty acid receptor CD36 promotes HCC progression through activating Src/PI3K/AKT axis-dependent aerobic glycolysis[J]. Cell Death Dis，2021，12（4）：328. DOI：10.1038/s41419-021-03596-w.
[37]	WANG L H，ZHU Z，LIANG Q，et al. A novel small molecule glycolysis inhibitor WZ35 exerts anti-cancer effect via metabolic reprogramming[J]. J Transl Med，2022，20（1）：530. DOI：10.1186/s12967-022-03758-0.
[38]	NG S S W，JANG G H，KURLAND I J，et al. Plasma metabolomic profiles in liver cancer patients following stereotactic body radiotherapy[J]. EBioMedicine，2020，59：102973.
[39]	王佳媛，袁依依，张坤，等. NDRG2通过调控肝癌细胞磷脂和甘油三酯代谢抑制肝细胞癌的生长：基于代谢组学分析[J]. 南方医科大学学报，2022，42（12）：1765-1773. DOI：10.12122/j.issn.1673-4254.2022.12.03.